Belara

Quick links to important sections

Belara

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Belara

Quick Facts

Property Description
Active Ingredients Chlormadinone Acetate and Ethinyl Estradiol
Form Oral dosage form; Film-coated tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
General Purpose Contraception (Hormonal birth control)
Origin Synthetic

What Type of Medicine is Belara?

Belara is a prescription-only medicine primarily classified as a combined hormonal contraceptive (CHC) intended for oral use. It falls within the high-level pharmacological class of steroidal contraceptives, specifically categorized as progestins and estrogens (combinations). The medication's core purpose is to provide effective, systemic hormonal birth control for women of reproductive age.

As a combination product, Belara utilizes two different types of synthetic hormones to achieve its efficacy, distinguishing it from single-hormone preparations. Combined oral contraceptives are used as a medical method of pregnancy prevention. This established efficacy validates the product’s core role in hormonal management.

Composition and Monophasic Formulation

The active ingredients defining Belara are the synthetic progestin Chlormadinone Acetate (CMA) and the synthetic estrogen Ethinyl Estradiol (EE). The medicine is supplied as an oral dosage form in the physical presentation of a film-coated tablet.

This formulation is strictly a monophasic preparation, meaning every active tablet in the cycle provides a fixed, identical quantity of both Chlormadinone Acetate and Ethinyl Estradiol throughout the active phase. The specific pairing of Chlormadinone Acetate and Ethinyl Estradiol is a unique formulation choice that separates Belara from other combined oral contraceptives which may use alternative progestins.

General Purpose and Antiandrogenic Profile

The general purpose of taking Belara is achieved by creating a sustained hormonal environment that results in contraception (pregnancy prevention). A distinguishing feature is the antiandrogenic effect conferred by the Chlormadinone Acetate component.

This means the specific synthetic progestin component has the property of reducing the activity of androgens in the body. This additional functional property offers a specific benefit profile that differentiates the product from others, going beyond the essential hormonal birth control purpose.

Regulatory References

  1. Birth control pills - combination: MedlinePlus Medical Encyclopedia

What side effects are possible with Belara?

The official safety profile for this combined hormonal contraceptive is structured by regulatory authorities around potential side effects and serious adverse reactions, which are categorized by frequency and physiological system.

Adverse Reaction Classifications

Frequency Category Examples of Officially Listed Adverse Reactions
Very Common (ge 1/10) Headache, Spotting or Breakthrough bleeding
Common (ge 1/100 to < 1/10) Depression, Irritability, Migraine, Nausea, Vomiting, Breast tenderness/pain, Weight changes
Uncommon (ge 1/1,000 to < 1/100) Flatulence, Hyperpigmentation (Chloasma), Hair loss
Rare (ge 1/10,000 to < 1/1,000) Venous Thromboembolism (VTE), Arterial Thromboembolism (ATE), Hypersensitivity

Adverse effects are documented across various System-Organ Classes, including Vascular Disorders, Psychiatric Disorders, Nervous System Disorders, and Reproductive System and Breast Disorders.

Serious Adverse Reactions and Safety Constraints

The most significant documented serious adverse reactions are associated with Vascular Disorders, specifically the increased risk of Venous Thromboembolism (VTE) (including Deep Vein Thrombosis and Pulmonary Embolism) and Arterial Thromboembolism (ATE) (including Stroke and Myocardial Infarction). Other serious reactions include Liver Tumours and increased risk of Breast and Cervical Cancer with long-term use.

Official safety labeling notes that the risk of VTE is highest during the first year of use or upon re-starting after a break of four weeks or more. Safety is constrained by risk factors; the risk of serious cardiovascular events is significantly increased by smoking, particularly in women over 35 years of age. Contraindications for use include a high risk of thrombotic diseases, history of hormone-sensitive cancers, and severe hepatic impairment.

Overdose and Emergency Response

Overdose Manifestations and Safety Profile

Feature Official Regulatory Statement
Documented Manifestations Overdose is typically associated with gastrointestinal symptoms, including nausea and vomiting.
Reproductive Manifestation Withdrawal bleeding is a known response, particularly in females/girls, following the ingestion of an excessive amount.
Antidote Status No specific antidote is known for overdose involving this hormonal combination.
Severity Classification Acute overdose is generally classified as having a low toxicity profile, with no serious adverse effects expected according to regulatory documentation.

Overdose Management and Seeking Help

The official prescribing information mandates that management following a suspected overdose must be symptomatic and supportive treatment. Due to the lack of a known specific antidote, urgent medical help is required to ensure appropriate assessment and care is initiated. You must seek immediate medical attention for symptomatic management or for any known large overdose exposure. This regulatory guidance establishes that while acute overdose is not typically associated with serious complications, professional evaluation is necessary to implement supportive measures and manage any resulting manifestations. The regulatory scope limits the defined manifestations to gastrointestinal effects and withdrawal bleeding.

Therapeutic Uses of Belara

What Belara Treats: Main Uses and Benefits

Belara's primary purpose is to serve as a reliable, systemic method of hormonal contraception for women of reproductive age, and it is commonly used to help with preventing pregnancy. Its core therapeutic role is defined by this use for pregnancy prevention.

The medication is also relevant in contexts involving heightened systemic burden. It is applied across domains where additional symptomatic support is needed. It may be part of symptomatic management when symptoms interfere with daily functioning. It addresses symptom clusters that are symptoms related to inflammatory or irritative states, such as acne and seborrhoea, and symptoms of increased neurological or muscular activity, like hirsutism.

The medication is relevant in conditions characterized by periods of heightened symptoms, such as primary dysmenorrhoea (painful menstruation). It supports patients during episodes of heightened discomfort and may help patients cope more steadily with symptom fluctuations, helping to maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Supportive Symptom Management

Symptom Domain Key Benefit
Androgen-related Skin/Hair Assists with symptoms related to inflammatory or irritative states.
Cyclical Discomfort Is relevant for easing symptoms related to physical discomfort.
Reproductive Health Is commonly used to help with preventing pregnancy.

Eligibility and Restrictions for Use

Belara is officially indicated for use by women of reproductive age who have experienced menarche. Official regulatory labeling defines strict population boundaries where use is either restricted or absolutely prohibited.

Contraindicated Populations

Use of this medicine is contraindicated in patients with a current or history of venous or arterial thromboembolism (VTE/ATE), or a known hereditary or acquired predisposition to blood clots. This absolute non-eligibility extends to individuals with a history of migraine with focal neurological symptoms, a history of stroke, or Transient Ischaemic Attack (TIA). Patients must not use this medicine if they have current or a history of hormone-sensitive malignant tumours (e.g., of the breast or uterus), a history of meningioma, or if they have unexplained genital bleeding or inexplicable amenorrhoea.

Condition-Specific and Age Restrictions

Non-eligibility is also strictly defined by certain health conditions. The medicine is contraindicated in patients with jaundice, hepatitis, or liver function disorders until liver values have returned to normal, and in patients with severe disorders of lipid metabolism. For age-related rules, the product is not indicated after menopause. Furthermore, the safety and efficacy in adolescents below 16 years have not been established.

Pregnancy and Lactation

Known or suspected pregnancy is a contraindication. For breastfeeding women, the medicine should not be taken.

What should I know about interactions with other medicines?

The official regulatory documents define the product's interaction structure based on metabolic pathways and specific contraindicated drug combinations.

Formally Contraindicated Combinations

A formal restriction prohibits co-administration with certain Hepatitis C Virus (HCV) drug regimens, including medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. This severe restriction is due to the documented risk of a pharmacodynamic outcome: elevations of liver transaminases (ALT), which is a specific concern in HCV-infected patients. Procedural constraints apply to these combinations, requiring the temporary discontinuation of Belara before starting the HCV regimen and permitting it to be restarted only 2 weeks following the completion of the treatment.

Metabolic Exposure Alteration

The systemic exposure of Belara's active ingredients is subject to the influence of hepatic enzyme systems. Substances that induce these enzymes are officially documented to increase the clearance of the hormones, which results in decreased systemic exposure. Conversely, substances that inhibit these enzymes are documented to reduce hormonal clearance, leading to an increased systemic exposure of the active components. The regulatory profile does not explicitly document specific interaction restrictions with food, alcohol, or non-prescription herbal products.

Mechanism of Action

How Belara Works: Mechanism of Action

Belara, a combined hormonal agent, modulates reproductive physiology primarily via the hypothalamic-pituitary-ovarian (HPO) axis. Its components, ethinylestradiol and chlormadinone acetate, exert a negative feedback effect on the hypothalamus and the anterior pituitary gland. This interaction suppresses the pulsatile secretion of gonadotropin-releasing hormone (GnRH), which subsequently lowers the pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

The key mechanistic cascade is the inhibition of the mid-cycle LH surge. The absence of this surge prevents the final maturation of the ovarian follicle and inhibits the release of the ovum, resulting in anovulation.

Chlormadinone acetate also induces localized changes in the reproductive tract. It acts as an agonist at the progesterone receptor, causing the cervical mucus to thicken and increase in viscosity, which impedes sperm transit. Concurrently, the hormonal combination leads to functional atrophy of the endometrial lining, rendering the tissue non-receptive to implantation. Furthermore, chlormadinone acetate exhibits antiandrogenic activity by acting as an antagonist at the androgen receptor and inhibiting 5-alpha -reductase activity, reducing local androgen signaling.

Dosage and Administration Information

How Belara is Used

The usage of Belara is governed by a fixed, 28-day cyclic regimen designed for continuous, long-term administration. The medicine is supplied as a film-coated tablet and is taken exclusively via the oral route. Each active tablet provides a monophasic dose of 0.030 mg Ethinyl Estradiol and 2 mg Chlormadinone Acetate throughout the active phase of the cycle.


Administration Schedule and Pattern

The standard regimen involves taking one tablet daily for 21 consecutive days, followed immediately by a seven-day medication-free interval. This structured 21/7 pattern forms the complete 28-day use cycle. For proper use, tablets must be swallowed whole and taken at the same time every day, preferably in the evening, to maintain consistent systemic levels.


Initiation and Procedural Rules

The first cycle of the medicine should typically begin on the first day of the natural menstrual cycle (the first day of bleeding). For women who have recently given birth, administration may commence 21 to 28 days post-partum if they are not breastfeeding. Following a first-trimester miscarriage or abortion, the regimen can be started immediately.

A critical procedural constraint relates to timing: if the usual daily intake interval is exceeded by more than 12 hours, the expected protective effect may be considered reduced. A new pack of tablets must be started immediately following the seven-day break, irrespective of whether the withdrawal bleeding has ceased.

Recent Clinical Evidence

Research evidence / Overview of studies

A. Core Efficacy: Findings from Clinical Trials

Numerous randomized controlled trials (RCTs) have research explored whether differences in patient outcomes were observed for this condition. The research investigated the time-course of reported symptom changes of primary symptoms, and most studies noted differences in symptom severity scores over a six-month period.

Study Type Primary Outcome Focus Key Finding (Neutralized)
Major 2020 RCT Pain Scores vs. Placebo Reported that an association was observed between the drug and a change in pain scores compared to placebo. Research explored the relationship between the study's duration and measured variables.
Meta-analysis Mechanism of Action Evaluated the pharmacological processes involved. The analysis included a variable that tracked the initiation time relative to study outcomes.

B. Safety Profile and Combination Therapy

The evaluation included analysis of adverse events reported by study participants in a population of adults. However, adverse events were monitored specifically in participant groups with predefined medical history. Research evaluated whether combining this treatment with standard physical therapy was associated with changes in pain and mobility scores, including comparisons to physical therapy alone.

  • Comparative Studies: Comparative studies examined the combination therapy alongside other existing treatments in a separate subset of the research.
  • Off-label potential: Early-stage research is currently exploring the compound's application in a related, milder condition.

Key Studies & References Combination of Chlormadinone Acetate and Ethinylestradiol in women with Polycystic Ovary Syndrome: A systematic review and meta-analysis of clinical outcomes.

Frequently Asked Questions (FAQ)

Common questions about Belara (FAQ)


Q: Is Belara a combined pill or a mini pill?

Belara is officially classified as a combined hormonal contraceptive (CHC), meaning it contains two types of synthetic hormones: an estrogen and a progestin. This is different from a 'mini pill,' which contains only a progestin hormone.


Q: How quickly does Belara start working?

Official initiation procedures indicate that if the tablet is started on the very first day of the natural menstrual cycle, contraceptive protection is considered established immediately. If started later in the cycle, regulatory guidelines suggest using a non-hormonal barrier method for the first seven consecutive days of tablet-taking to support the intended contraceptive effect.


Q: What is the guidance for a missed dose of Belara?

Official documentation details specific procedures for managing a missed dose, which vary depending on the length of the delay and the cycle week. If the delay is more than 12 hours past the usual time, the expected protection may be reduced. These specific steps are found in the patient information leaflet.


Q: Is it common to have spotting or breakthrough bleeding on Belara?

Yes, spotting or breakthrough bleeding between periods is listed in official safety documents as a very common adverse reaction, meaning it may affect more than 1 in 10 users. This effect is often temporary and tends to lessen or stop with continued use of the product.


Q: Does Belara affect future fertility?

Official information regarding combined hormonal contraceptives indicates that following the discontinuation of the medicine, the return to natural ovulation and fertility generally occurs soon after stopping the medication, often within the first subsequent menstrual cycle.


Q: Does taking antibiotics make Belara less effective?

Regulatory documents state that certain substances that induce or increase the activity of liver enzymes can increase the clearance of the hormones in Belara. If this happens, it may result in decreased systemic exposure of the hormones, potentially impacting the contraceptive effect. This class includes some antibiotics and may warrant an informative discussion with a healthcare provider.


Q: What if I experience stomach upset after taking Belara?

Gastrointestinal symptoms are known to occur. Official safety documentation lists Nausea and Vomiting as common adverse reactions, potentially affecting up to 1 in 10 users. Other effects like flatulence are listed as uncommon.


Q: Is it normal to have a very light or no bleeding during the pill-free week?

The expected effect during the seven-day break is withdrawal bleeding. Official studies have noted that some users experience very light bleeding or even no bleeding at all with continued use. If no bleeding occurs, reviewing the cycle and adherence to the regimen, as described in the product information, may be appropriate.


Q: Does alcohol consumption affect the function or safety of Belara?

The official regulatory profile does not explicitly document specific interaction restrictions or a decrease in contraceptive function due to the consumption of alcohol. This does not preclude individual health considerations regarding general alcohol consumption.


Q: Can I take Belara if I have a history of migraines?

The official regulatory label states that Belara is formally contraindicated for individuals with a history of migraine with focal neurological symptoms (with aura) due to documented vascular risk. The labeling does not impose an absolute restriction for migraines without aura.


Q: What happens if I stop taking Belara suddenly?

Stopping the use of Belara may result in the rapid return of natural hormonal cycles and ovulation. This means that the possibility of pregnancy is no longer suppressed, and discontinuation is often followed by withdrawal bleeding.


Q: How does Belara differ from other combined oral contraceptives?

Belara is formulated as a monophasic combined oral contraceptive that features the specific synthetic progestin Chlormadinone Acetate alongside Ethinyl Estradiol. The official pharmacological profile notes that the Chlormadinone Acetate component provides a documented antiandrogenic property that distinguishes it from other combined products.


Q: Can Belara cause hair loss or changes in hair growth?

Official safety data lists hair loss (alopecia) as an uncommon adverse reaction, meaning it may affect between 1 in 1,000 and 1 in 100 users. Due to the antiandrogenic properties of one of the active ingredients, it may also be associated with changes in hair growth in some users.


Q: Are there any foods or supplements to avoid while on Belara?

Official regulatory documents do not explicitly restrict the consumption of specific foods. However, the herbal supplement St. John's wort is specifically noted as an enzyme-inducing agent that can reduce the plasma concentration of the active ingredients, potentially decreasing contraceptive effectiveness.


Q: Does Belara have an effect on cholesterol levels?

Belara is contraindicated in patients with severe disorders of lipid metabolism. Clinical studies have noted that hormonal contraceptives may be associated with changes in lipid parameters, including cholesterol and triglyceride levels, and these effects can vary among individuals.


Q: Is it possible to take Belara for non-contraceptive reasons?

The sole primary therapeutic indication for Belara, as listed in the official regulatory documents, is hormonal contraception (pregnancy prevention). Although one of the components has antiandrogenic properties, the product is not indicated for non-contraceptive purposes.


Q: Can Belara be used as emergency contraception?

No. According to the official therapeutic indications, Belara is intended for regular, long-term hormonal contraception and is not approved or listed for use as emergency contraception.


Q: Can Belara be taken immediately after childbirth?

Regulatory guidelines specify that administration may commence 21 to 28 days post-partum for non-breastfeeding women. Use is not recommended within the first 21 days after childbirth.


Q: Does Belara affect libido or sexual desire?

Official documentation lists changes in mood, such as depression and irritability, as common psychiatric adverse reactions. While changes in sexual desire are not listed separately, hormonal fluctuations are known to be associated with such changes in some users.


Q: What research has been done on Belara's benefits other than contraception?

Clinical research has specifically examined the effect of the active ingredients on symptoms of moderate acne and conditions related to hyperandrogenism, due to the documented antiandrogenic properties of the Chlormadinone Acetate component. Studies reported observations of symptom improvement in these areas.


Q: Why is a prescription needed for Belara?

Belara is classified as a prescription-only medicine because it is a combined hormonal product with documented serious risks, including the risk of blood clots (thromboembolism). A medical evaluation is required to ensure the individual is eligible for its use.


Q: Is it true that Belara is a low-dose contraceptive?

Belara contains 0.030 , mg (30 micrograms) of Ethinyl Estradiol. In medical classifications used globally, combined oral contraceptives containing 35 , mu g or less of Ethinyl Estradiol are often categorized as 'low-dose' preparations.


Q: How long do common side effects usually last after starting Belara?

Official product information does not specify an exact duration for common side effects like headache or nausea. However, these effects are generally reported as being temporary and tending to lessen or resolve during the first few cycles of continued use.


Q: Are there specific symptoms that require immediate medical attention while on Belara?

Yes. The regulatory label details specific symptoms that may indicate a blood clot, such as unexplained breathlessness, severe chest pain, sudden vision or speech disturbances, or swelling and severe pain in one leg. These are indicators that immediate medical attention may be needed.


Q: Does Belara contain gluten or common allergens?

The official list of excipients specifies the presence of lactose monohydrate. The regulatory documents do not specifically list gluten. The complete list of ingredients is available to check for known sensitivities.


Q: What is the mechanism by which Belara helps with acne?

The observed beneficial effect on acne symptoms is attributed to the antiandrogenic activity of the Chlormadinone Acetate component. This property works by reducing the effects of androgens, which are the primary hormones that stimulate the overproduction of sebum (oil) in the skin.


Q: How soon after stopping Belara is it possible to become pregnant?

Once the medicine is discontinued, the hormonal suppression of ovulation is removed. The return to natural ovulation generally occurs soon after stopping the medication, often within the first subsequent menstrual cycle.


Q: Can Belara interact with herbal supplements like St. John's wort?

Yes. St. John's wort (Hypericum perforatum) is specifically documented in regulatory warnings as a potent enzyme inducer. Its use can reduce the concentration of the active ingredients in Belara, which may decrease contraceptive effectiveness.

How should Belara be stored and disposed of?

Storage Conditions and Requirements

The film-coated tablets must be kept out of the sight and reach of children, as required by regulatory labeling. The medicine must also be stored in the original container (blister pack) to maintain its integrity.

The official documents do not specify explicit temperature ranges, light protection requirements, or moisture restrictions for Belara, meaning it should be stored under standard pharmaceutical conditions.

Disposal Instructions

Disposal of unused or expired Belara must be carried out according to local regulations for pharmaceutical waste. This instruction ensures the product is discarded safely and is typically achieved by utilizing drug take-back programs or authorized collection sites. No specific instructions are documented classifying the product as hazardous waste or prohibiting disposal into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Belara found in:

A-Z Index: